Spectral Medical Announces Opening of Tigris Clinical Trial Site at the Mayo Clinic

TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the onboarding of the Mayo Clinic in Rochester, Minnesota, as its 19th clinical site for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults being treated for endotoxemia and septic shock. The Mayo Clinic is a premier medical center in the U.S. and is top ranked in more specialties than any other hospital in the nation, according to U.S. News & World Report.
        
Dr. John Kellum, Chief Medical Officer of Spectral, commented, “We are pleased to announce the addition of the Mayo Clinic to the premier roster of clinical trial sites participating in Tigris. Moreover, we are making continued progress enrolling additional sites, and are on track to add an additional six sites in the coming four to six weeks. We remain highly encouraged by the outlook for the trial, given both the current enrollment rates and preliminary mortality data.”

Read more at globenewswire.com